Home/RosVivo Therapeutics/Sandra M. Poudrier

SM

Sandra M. Poudrier

Chief Operating Officer

RosVivo Therapeutics

Therapeutic Areas

Metabolic Diseases Diabetes Obesity NAFLD Gastrointestinal Disorders

RosVivo Therapeutics Pipeline

Drug	Indication	Phase
RSVI-301	Diabetes (with planned expansion to Obesity, NAFLD, GI disorders)	Pre-clinical
RSVI-302	Diabetes and Obesity	Pre-clinical

Leadership Team at RosVivo Therapeutics

President and Chief Scientific Officer

Chief Executive Officer

View full RosVivo Therapeutics profile